Xsss
J Mult Scler Res. 2021; 1(1): 13-16 | DOI: 10.4274/jmsr.galenos.2021.6-1
2Dokuz Eylul University, Institute of Health Sciences, Department of Neurosciences, Izmir, Turkey
3Izmir Katip Celebi University Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Izmir, Turkey
Challenges of Patients with Neuromyelitis Optica Spectrum Disorder During COVID-19 Pandemic
Serkan Ozakbas1, Cavid Baba2, Pelin Hancer2, Ozge Sagici2, Asiye Tuba Ozdogar2, Zuhal Abasıyanık3, Seda Dastan21Dokuz Eylul University Faculty of Medicine, Department of Neurology, Izmir, Turkey2Dokuz Eylul University, Institute of Health Sciences, Department of Neurosciences, Izmir, Turkey
3Izmir Katip Celebi University Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Izmir, Turkey
INTRODUCTION: At present, millions of people have been infected and hundreds of thousands are falling dead because of Coronavirus disease-2019.
People with neuromyelitis optica spectrum disorder (NMOSD) are among patients who use immunosuppressive drugs.
METHODS: Registered patients with NMOSD were contacted via phone during the three-months of pandemic.
RESULTS: Information from 45 patients was gathered, and three (8.57%) of them stopped their treatment due to fear for immunosuppression. All
three were on rituximab treatment.
DISCUSSION AND CONCLUSION: Infusion therapy was assumed to pose more fear in terms of immunosuppression on patients compared with noninfusion route of
treatment.
Corresponding Author: Cavid Baba, Türkiye
Manuscript Language: English
Manuscript Language: English
Copyright © 2025 | Journal of Multiple Sclerosis Research